Research ArticleOriginal Article

Perioperative rh-endostatin with chemotherapy improves the survival of conventional osteosarcoma patients: a prospective non-randomized controlled study

Hairong Xu, Zhen Huang, Yuan Li, Qing Zhang, Lin Hao and Xiaohui Niu
Cancer Biology & Medicine February 2019, 16 (1) 166-172; DOI: https://doi.org/10.20892/j.issn.2095-3941.2018.0315

References

  1. 1.↵
    2. Bielack SS,
    3. Kempf-Bielack B,
    4. Delling G,
    5. Exner GU,
    6. Flege S,
    7. Helmke K, et al.
    Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002; 20: 776–90.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    2. Lewis IJ,
    3. Nooij MA,
    4. Whelan J,
    5. Sydes MR,
    6. Grimer R,
    7. Hogendoorn PCW, et al.
    Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007; 99: 112–28.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    2. Bacci G,
    3. Briccoli A,
    4. Ferrari S,
    5. Longhi A,
    6. Mercuri M,
    7. Capanna R, et al.
    Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer. 2001; 37: 2030–9.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    2. Provisor AJ,
    3. Ettinger LJ,
    4. Nachman JB,
    5. Krailo MD,
    6. Makley JT,
    7. Yunis EJ, et al.
    Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol. 1997; 15: 76–84.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    2. Anninga JK,
    3. Gelderblom H,
    4. Fiocco M,
    5. Kroep JR,
    6. Taminiau AHM,
    7. Hogendoorn PCW, et al.
    Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand? Eur J Cancer. 2011; 47: 2431–45.
    OpenUrlCrossRefPubMed
  6. 6.↵
    2. Wang J,
    3. Gu LJ,
    4. Fu CX,
    5. Cao Z,
    6. Chen QY.
    Endostar combined with chemotherapy compared with chemotherapy alone in the treatment of nonsmall lung carcinoma: A meta-analysis based on Chinese patients. Indian J Cancer. 2014; 51 Suppl 3: e106–9.
  7. 7.↵
    2. Wang JW,
    3. Sun Y,
    4. Liu YY,
    5. Yu QT,
    6. Zhang YP,
    7. Li K, et al.
    Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Chin J Lung Cancer. 2005; 8: 283–90.
    OpenUrl
  8. 8.↵
    2. Xu HR,
    3. Niu XH,
    4. Zhang Q,
    5. Hao L,
    6. Ding Y,
    7. Liu WF, et al.
    Synergistic antitumor efficacy by combining adriamycin with recombinant human endostatin in an osteosarcoma model. Oncol Lett. 2011; 2: 773–8.
    OpenUrlPubMed
  9. 9.↵
    2. Enneking WF,
    3. Spanier SS,
    4. Goodman MA.
    A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980:106-20.
  10. 10.↵
    2. Trotti A,
    3. Byhardt R,
    4. Stetz J,
    5. Gwede C,
    6. Corn B,
    7. Fu K, et al.
    Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000; 47: 13–47.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    2. Kaste SC,
    3. Liu T,
    4. Billups CA,
    5. Daw NC,
    6. Pratt CB,
    7. Meyer WH.
    Tumor size as a predictor of outcome in pediatric non-metastatic osteosarcoma of the extremity. Pediatr Blood Cancer. 2004; 43: 723–8.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    2. Jaffe N,
    3. Bruland OS,
    4. Bielack S.
    2. Jaffe N.
    Osteosarcoma: review of the past, impact on the future. The American experience. In: Jaffe N, Bruland OS, Bielack S. Pediatric and Adolescent Osteosarcoma. Boston, MA: Springer; 2009; 239-62.
  13. 13.↵
    2. Smeland S,
    3. Wiebe T,
    4. Böhling T,
    5. Brosjö O,
    6. Jonsson K,
    7. Alvegård TA.
    Chemotherapy in osteosarcoma: The Scandinavian Sarcoma Group experience. Acta Orthop Scand. 2004; 75: 92–8.
    OpenUrl
  14. 14.↵
    2. Rosen G,
    3. Suwansirikul S,
    4. Kwon C,
    5. Tan C,
    6. Wu SJ,
    7. Beattie EJ, et al.
    High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma. Cancer. 1974; 33: 1151–63.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    2. Rosen G,
    3. Tan C,
    4. Sanmaneechai A,
    5. Beattie EJ Jr.,
    6. Marcove R,
    7. Murphy ML.
    The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma. Cancer. 1975; 35: 936–45.
    OpenUrlPubMed
  16. 16.↵
    2. Stephens EH,
    3. Blackmon SH,
    4. Correa AM,
    5. Roth JA,
    6. Rice DC,
    7. Hofstetter W, et al.
    Progression after chemotherapy is a novel predictor of poor outcomes after pulmonary metastasectomy in sarcoma patients. J Am Coll Surg. 2011; 212: 821–6.
    OpenUrlCrossRefPubMed
  17. 17.↵
    2. Rasalkar DD,
    3. Chu WCW,
    4. Lee V,
    5. Paunipagar BK,
    6. Cheng FWT,
    7. Li CK.
    Pulmonary metastases in children with osteosarcoma: characteristics and impact on patient survival. Pediatr Radiol. 2011; 41: 227–36.
    OpenUrlPubMed
  18. 18.↵
    2. Folkman J.
    Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285: 1182–6.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    2. Abdollahi A,
    3. Folkman J.
    Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat. 2010; 13: 16–28.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    2. Kaya M,
    3. Wada T,
    4. Kawaguchi S,
    5. Nagoya S,
    6. Yamashita T,
    7. Abe Y, et al.
    Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br J Cancer. 2002; 86: 864–9.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    2. Dutour A,
    3. Monteil J,
    4. Paraf F,
    5. Charissoux JL,
    6. Kaletta C,
    7. Sauer B, et al.
    Endostatin cDNA/cationic liposome complexes as a promising therapy to prevent lung metastases in osteosarcoma: study in a human-like rat orthotopic tumor. Mol Ther. 2005; 11: 311–9.
    OpenUrlPubMedWeb of Science
  22. 22.↵
    2. Xu HR,
    3. Tian W,
    4. Niu XH,
    5. Yuan RY,
    6. Zhang Q,
    7. Chen DF, et al.
    In vitro study of recombinant human endostatin in combination with adriamycin on human osteosarcoma cell OS-732. Chin J Bone Tumor Bone Disease. 2008; 7: 129–32.
    OpenUrl
  23. 23.↵
    2. Jeffree GM,
    3. Price CH,
    4. Sissons HA.
    The metastatic patterns of osteosarcoma. Br J Cancer. 1975; 32: 87–107.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    2. Tsunemi T,
    3. Nagoya S,
    4. Kaya M,
    5. Kawaguchi S,
    6. Wada T,
    7. Yamashita T, et al.
    Postoperative progression of pulmonary metastasis in osteosarcoma. Clin Orthop Relat Res. 2003; 407: 159–66.
    OpenUrl
  25. 25.↵
    2. Folkman J.
    Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg. 1972; 175: 409–16.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    2. Quan GMY,
    3. Choong PFM.
    Anti-angiogenic therapy for osteosarcoma. Cancer Metastasis Rev. 2006; 25: 707–13.
    OpenUrlPubMed
  27. 27.↵
    2. Jain RK.
    Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001; 7: 987–9.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    2. Wagner LM,
    3. Fouladi M,
    4. Ahmed A,
    5. Krailo MD,
    6. Weigel B,
    7. DuBois SG, et al.
    Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2015; 62: 440–4.
    OpenUrlCrossRefPubMed
  29. 29.
    2. Schuetze SM,
    3. Zhao LL,
    4. Chugh R,
    5. Thomas DG,
    6. Lucas DR,
    7. Metko G, et al.
    Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma. Eur J Cancer. 2012; 48: 1347–53.
    OpenUrlCrossRefPubMed
  30. 30.
    2. Schwartz GK,
    3. Tap WD,
    4. Qin LX,
    5. Livingston MB,
    6. Undevia SD,
    7. Chmielowski B, et al.
    Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013; 14: 371–82.
    OpenUrlCrossRefPubMed
  31. 31.↵
    2. Schuetze SM,
    3. Wathen JK,
    4. Lucas DR,
    5. Choy E,
    6. Samuels BL,
    7. Staddon AP, et al.
    SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer. 2016; 122: 868–74.
    OpenUrl
  32. 32.↵
    2. Bacci G,
    3. Longhi A,
    4. Versari M,
    5. Mercuri M,
    6. Briccoli A,
    7. Picci P.
    Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006; 106: 1154–61.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    2. Li BL,
    3. Hu XL,
    4. Zhao XH,
    5. Sun HG,
    6. Zhou CY,
    7. Zhang Y.
    Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: A clinical study. J Chemother. 2015; 27: 301–6.
    OpenUrl
  34. 34.
    2. An JH,
    3. Lv WL.
    Endostar (rh-endostatin) versus placebo in combination with vinorelbine plus cisplatin chemotherapy regimen in treatment of advanced non-small cell lung cancer: A meta-analysis. Thorac Cancer. 2018; 9: 606–12.
    OpenUrl
  35. 35.
    2. Lu S,
    3. Li L,
    4. Luo Y,
    5. Zhang L,
    6. Wu G,
    7. Chen ZW, et al.
    A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer. J Thorac Oncol. 2015; 10: 206–11.
    OpenUrl
  36. 36.↵
    2. Guan Y,
    3. Li AC,
    4. Xiao WW,
    5. Liu S,
    6. Chen BB,
    7. Lu TX, et al.
    The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma. Oncotarget. 2015; 6: 33926–34.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords